Unicorn Capital Partners, managing company of PharmMed Innovations venture fund, acted as the lead investor in a round B investment in Intellogic. The total size of the round amounted to 160 million rubles. and aims to further develop the Botkin.AI artificial intelligence platform for medical research analysis, ensure scaling, expand sales in Russia and enter international markets. The co-investor of the round was the investment holding Tashir MEDICA, which specializes in financing and strategic development of assets in the healthcare sector. All current investors of the company also participated in the round - venture funds RBV Capital, Digital Evolution Ventures (MC Orbita Capital Partners), PrimerCapital and ExpoCapital.
The Botkin.AI platform is designed to analyze and identify pathologies in diagnostic studies using computed tomography, X-ray, and mammography. The project uses its own patented technology for creating mathematical models of patients based on artificial intelligence. The Botkin.AI platform has the only registration certificate in the Russian Federation of Roszdravnadzor as a medical device with artificial intelligence technology of risk class 2b, which allows the platform to be used in diagnostics, including diseases that have a high risk to health, such as cancer, as well as for screening . The platform is already commercially used by radiologists in a number of Russian regions and pilot projects abroad. The Botkin.AI project was noted as a successful leadership project at a meeting of the President with members of the Government of the Russian Federation on December 9, 2020, held on the topic of developing high-tech areas.
The company has formed a scientific and medical advisory council, which is headed by the president of the Russian Society of Radiologists and Radiologists, ex-president of the European Congress of Radiology, head of the radiology course at the Faculty of Fundamental Medicine of Moscow State University. M.V. Lomonosov, Doctor of Medical Sciences, Professor Valentin Sinitsyn.
Maxim Gorbachev, Managing Partner at Unicorn Capital Partners:
“The coronavirus pandemic has spurred the already high interest in artificial intelligence technologies in medicine, opening up a number of new opportunities for the successful commercial implementation of the Botkin AI platform in medical practice. Intellogic combines a professional team, world-class developments and a first-class syndicate of investors, which makes it an attractive investment object.»;
Sergey Sorokin, CEO of Intellogic LLC, founder of the Botkin.AI project:
“Our project is entering a new level of development. The technologies we have allow us to develop our platform as a complex product of a fundamentally new class for the medical research analysis market. New investments and shareholders will help us not only strengthen our leadership in the Russian market, but also become a prominent player in the international arena”;
Alexey Basov, Deputy General Director - Investment Director of RVC:
The PharmMed Innovations Venture Fund was created to support breakthrough domestic technologies in the field of medicine and pharmaceuticals. For RVC, as a key investor in the fund, it is very important that the team has started the investment cycle and is actively building a portfolio of projects. Botkin.AI is one of the leaders in the AI-based medical diagnostics segment. Today, such projects are in demand not only in the Russian market, but also internationally”;
Alexey Alekhin, Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of Russia:
“The platform received the only registration certificate in Russia as a medical device with artificial intelligence technology of risk class 2b. The use of AI, of course, expands the capabilities of the Russian medical industry, especially in the field of functional diagnostics, including the diagnosis of diseases that are at high risk to health, such as cancer, as well as for screening.”
Sergey Morozov, Professor, Doctor of Medical Sciences, Chief Specialist in Radiation and Instrumental Diagnostics in Moscow and the Central Federal District, Director of the SPCC for Diagnostics and Telemedicine, DZM:
“As part of the Experiment on the use of innovative technologies in the field of computer vision for the analysis of medical images and further application in the Moscow healthcare system, from 03/02/2020 to 12/07/2020, the Botkin.AI artificial intelligence service of LLC "Intellogic".
The Botkin.AI service is positioned by the manufacturer as a Russian software platform based on artificial intelligence technology that helps radiologists and oncologists analyze CT images, digital
x-ray and mammography examinations with lower costs and higher accuracy.
During the approbation, the qualities were evaluated that allow for a complete, seamless and conflict-free integration of the platform into the Unified Radiological Information Service of the Automated Information System of the City of Moscow "Unified Medical Information and Analytical System of the City of Moscow".
As part of the approbation of the Botkin.AI Service, it was built into and connected to 139 diagnostic devices in various medical organizations in Moscow, as a result of which more than 150 thousand studies were processed.
Valentin Sinitsyn, Professor, Doctor of Medical Sciences, President of the Russian Society of Radiologists and Radiologists, Head of the Radiation Diagnostics Course at the Faculty of Fundamental Medicine of the Lomonosov Moscow State University. M.V.:
“Artificial intelligence for diagnostic image analysis has been the most discussed topic in radiology over the past 5 years. The experience of our cooperation with the Intellogic company shows that its management and employees have chosen the strategic goals for the development and sale of its products quite correctly. We successfully use the Botkin.AI platform for both scientific and practical purposes. I am glad that the domestic company works at such a high level, achieves its goals, grows dynamically and has ambitious plans for the near future.”
The Botkin.AI platform is designed to analyze and identify pathologies in diagnostic studies using computed tomography, X-ray, and mammography. The project uses its own patented technology for creating mathematical models of patients based on artificial intelligence. The Botkin.AI platform has the only registration certificate in the Russian Federation of Roszdravnadzor as a medical device with artificial intelligence technology of risk class 2b, which allows the platform to be used in diagnostics, including diseases that have a high risk to health, such as cancer, as well as for screening . The platform is already commercially used by radiologists in a number of Russian regions and pilot projects abroad. The Botkin.AI project was noted as a successful leadership project at a meeting of the President with members of the Government of the Russian Federation on December 9, 2020, held on the topic of developing high-tech areas.
The company has formed a scientific and medical advisory council, which is headed by the president of the Russian Society of Radiologists and Radiologists, ex-president of the European Congress of Radiology, head of the radiology course at the Faculty of Fundamental Medicine of Moscow State University. M.V. Lomonosov, Doctor of Medical Sciences, Professor Valentin Sinitsyn.
Maxim Gorbachev, Managing Partner at Unicorn Capital Partners:
“The coronavirus pandemic has spurred the already high interest in artificial intelligence technologies in medicine, opening up a number of new opportunities for the successful commercial implementation of the Botkin AI platform in medical practice. Intellogic combines a professional team, world-class developments and a first-class syndicate of investors, which makes it an attractive investment object.»;
Sergey Sorokin, CEO of Intellogic LLC, founder of the Botkin.AI project:
“Our project is entering a new level of development. The technologies we have allow us to develop our platform as a complex product of a fundamentally new class for the medical research analysis market. New investments and shareholders will help us not only strengthen our leadership in the Russian market, but also become a prominent player in the international arena”;
Alexey Basov, Deputy General Director - Investment Director of RVC:
The PharmMed Innovations Venture Fund was created to support breakthrough domestic technologies in the field of medicine and pharmaceuticals. For RVC, as a key investor in the fund, it is very important that the team has started the investment cycle and is actively building a portfolio of projects. Botkin.AI is one of the leaders in the AI-based medical diagnostics segment. Today, such projects are in demand not only in the Russian market, but also internationally”;
Alexey Alekhin, Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of Russia:
“The platform received the only registration certificate in Russia as a medical device with artificial intelligence technology of risk class 2b. The use of AI, of course, expands the capabilities of the Russian medical industry, especially in the field of functional diagnostics, including the diagnosis of diseases that are at high risk to health, such as cancer, as well as for screening.”
Sergey Morozov, Professor, Doctor of Medical Sciences, Chief Specialist in Radiation and Instrumental Diagnostics in Moscow and the Central Federal District, Director of the SPCC for Diagnostics and Telemedicine, DZM:
“As part of the Experiment on the use of innovative technologies in the field of computer vision for the analysis of medical images and further application in the Moscow healthcare system, from 03/02/2020 to 12/07/2020, the Botkin.AI artificial intelligence service of LLC "Intellogic".
The Botkin.AI service is positioned by the manufacturer as a Russian software platform based on artificial intelligence technology that helps radiologists and oncologists analyze CT images, digital
x-ray and mammography examinations with lower costs and higher accuracy.
During the approbation, the qualities were evaluated that allow for a complete, seamless and conflict-free integration of the platform into the Unified Radiological Information Service of the Automated Information System of the City of Moscow "Unified Medical Information and Analytical System of the City of Moscow".
As part of the approbation of the Botkin.AI Service, it was built into and connected to 139 diagnostic devices in various medical organizations in Moscow, as a result of which more than 150 thousand studies were processed.
Valentin Sinitsyn, Professor, Doctor of Medical Sciences, President of the Russian Society of Radiologists and Radiologists, Head of the Radiation Diagnostics Course at the Faculty of Fundamental Medicine of the Lomonosov Moscow State University. M.V.:
“Artificial intelligence for diagnostic image analysis has been the most discussed topic in radiology over the past 5 years. The experience of our cooperation with the Intellogic company shows that its management and employees have chosen the strategic goals for the development and sale of its products quite correctly. We successfully use the Botkin.AI platform for both scientific and practical purposes. I am glad that the domestic company works at such a high level, achieves its goals, grows dynamically and has ambitious plans for the near future.”